Sionna Therapeutics is trading 8.26% down in pre-market at $5.93, with the immediate trigger unclear.
- It rose 7.13% to $6.46 on September 1, 2026.
- No new company-specific announcement dated September 2 was identified; its latest listed release was its August 6, 2026 second-quarter results.
- The August 10 Phase 2a failure for SION-719 is stale and does not clearly explain the move; broader futures are only modestly lower.